Select Page

IMAGING THE RETINA

EarlySight is developing a medical device to help doctors detect and treat eye diseases at an early-stage thanks to precise measurement of the eye condition.

BECAUSE EYESIGHT MATTERS

 

Blindness and severe vision impairment consecutive to eye diseases affects more than 200 million people worldwide. Indeed, current diagnosis come up too late and treatment is not optimal for many diseases. The reason is the difficulty of assessing the disease state and the treatment effect due to the limitations of the standard imaging instruments.

At EarlySight, we are developing a unique eye fundus camera that can observe the tissue degenerative process associated with retinal diseases and detect its evolution, enabling potential early diagnosis and better treatments. The instrument is able to image the retina in a very detailed way (10 times increased precision) by coupling an innovative illumination of the eye with real-time ocular aberration correction. 

 

OBSERVE THE CELLULAR STRUCTURE

 

Automatic segmentation and quantification of the retinal pigment epithelium layer. Understand and visualize the origins of many diseases such as age-related macular degeneration. Measure the cell density or size and use quantitative metrics as bio-markers and therapeutic endpoints.

 

 

UP TO THE SMALLEST CAPILLARIES

 

Observe the vascular layer with details never seen before. The micro-vasculature structure and the small capillaries being micron-thick are visible with EarlySight technology. And even if no blood flow is present. Making it the ideal instrument to visualize micro-aneurysms.

FEEDBACK FROM EYE DOCTORS

 

“As the RPE plays an important role in many retinal diseases, assessing the microstructure on a cellular level looks very promising. With upcoming drugs, at present in phase 3 trials, for dry AMD, we are possibly on the border of an new age in ophthalmology where dry AMD can be treated. A detailed assessment of the RPE will be crucial for monitoring  treatment”

“This looks very interesting and is new compared to what is known from a research point of view”

“It is an improvement in technology and is attractive for research hospitals”

 

FEEDBACK FROM EYE DOCTORS

 

“Interesting to be able to look at RPE and glial cells – this cannot be seen with methods known today”

“Retinal imaging is today limited by lack of contrast”

“It might be possible with this new technology to see new disease patterns”

THEY SUPPORT US